Patients are bullish on the benefits of genAI, but still have qualms

Patients are bullish on the benefits of genAI, but still have qualms

U.S. consumers remain optimistic about the potential of generative artificial intelligence to address healthcare access and affordability challenges, the new 2024 Deloitte Center for Health Solutions consumer survey shows. But they still have some misgivings about AI tools.


Despite a general sense of optimism, the public's use of genAI tools for health-related reasons has dipped a bit since the initial rush of interest that showed in the previous year's Deloitte study – with 37% of consumers using it in 2024 versus 40% in 2023. 

One of the most prominent reasons for the stagnant adoption, researchers find, is distrust in AI outputs, which the report shows increased 7% since last year.

To boost trust in genAI tools, healthcare organizations must align the technology with the values, expectations and trust of patients, Deloitte advises in the new report.

Of the more than 2,000 U.S. adults surveyed in March 2024 about their use of genAI, 66% think it could reduce extended wait times for doctor’s appointments and lower individual healthcare costs.

Read on

Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.

© 2024 Netspective Media LLC. All Rights Reserved.

Built on Jun 17, 2024 at 5:47am